Role of modified cardiovascular risk factors in development of oncologic diseases
E. Yu. Zvolinskaya,
M. N. Mamedov,
V. I. Potievskaya,
S. A. Ivanov,
A. D. Kaprin no conflict of interest
https://doi.org/10.18087/cardio.2020.9.n910
Abstract
Cardiovascular (CVD) and oncological diseases (OD) are the main causes of death worldwide and account for a heavy burden on economy, disability and mortality in many countries. Clear understanding of the mechanisms shared by CVD and cancer is important for increasing the life span and quality of life in cancer survivors as well as for preventing comorbidities and correct instructing the patients about risk factors and lifestyle modifications. Both groups of diseases share risk factors, including smoking, obesity, diabetes mellitus, alcohol consumption, unhealthy diet, etc. Along with these factors, inflammation may play a key role as it promotes both types of diseases and accompanies obesity, diabetes mellitus, arterial hypertension, and dyslipidemia. Better understanding of the interaction between CVD and cancer will allow creating common effective diagnostic and preventive strategies and safe approaches to the treatment.
Supporting agencies: No conflict of interest is reported.
About the Authors
E. Yu. Zvolinskaya
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare, Moscow, Russia
Russian Federation
Russian Federation
PhD., main researcher of Department of Rehabilitation and Secondary Prevention of Combined Pathology of National Medical Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation
M. N. Mamedov
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare, Moscow, Russia
Russian Federation
PhD., MD, head of Department of Rehabilitation and Secondary Prevention of Combined Pathology of National Medical Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation
Russian Federation
PhD., MD, head of Department of Rehabilitation and Secondary Prevention of Combined Pathology of National Medical Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation
V. I. Potievskaya
National Medical Radiology Research Center of the Ministry of Healthcare, Moscow, Russia
Russian Federation
PhD., MD, chief researcher of Federal State Budgetary Institution National Medical Radiology Research Center of the Health Ministry of Russia
Russian Federation
PhD., MD, chief researcher of Federal State Budgetary Institution National Medical Radiology Research Center of the Health Ministry of Russia
S. A. Ivanov
Medical Radiological Research Center the branch of National Medical Radiology Research Center of the Ministry of Healthcare, Obninsk, Russia
Russian Federation
PhD., MD, director of A.F. Tsyb Medical Radiological Research Center the branch of Federal State Budgetary Institution National Medical Radiology Research Center of the Health Ministry of Russia
Russian Federation
PhD., MD, director of A.F. Tsyb Medical Radiological Research Center the branch of Federal State Budgetary Institution National Medical Radiology Research Center of the Health Ministry of Russia
A. D. Kaprin
National Medical Radiology Research Center of the Ministry of Healthcare, Moscow, Russia
Russian Federation
PhD., MD, Academician of Russian Academy of Science, General director of Federal State Budgetary Institution National Medical Radiology Research Center of the Health Ministry of Russia
Russian Federation
PhD., MD, Academician of Russian Academy of Science, General director of Federal State Budgetary Institution National Medical Radiology Research Center of the Health Ministry of Russia
References
1. World Health Organization. World health statistics 2018: monitoring health for the SDGs. 2018. ISBN 978-92-4-156558-5
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394–424. DOI: 10.3322/caac.21492
3. Lee H, Cho J, Shin DW, Lee S-P, Hwang S-S, Oh J et al. Association of cardiovascular health screening with mortality, clinical outcomes, and health care cost: A nationwide cohort study. Preventive Medicine. 2015;70:19–25. DOI: 10.1016/j.ypmed.2014.11.007
4. Federal State Statistics Service. Death statistics according to Rosstat. Av. at: https://rosinfostat.ru/smertnost/.
5. Van Hemelrijck M, Folkvaljon Y, Adolfsson J, Akre O, Holmberg L, Garmo H et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU International. 2016;117(3):507–14. DOI: 10.1111/bju.13059
6. Handy CE, Quispe R, Pinto X, Blaha MJ, Blumenthal RS, Michos ED et al. Synergistic Opportunities in the Interplay Between Cancer Screening and Cardiovascular Disease Risk Assessment: Together We Are Stronger. Circulation. 2018;138(7):727–34. DOI: 10.1161/CIRCULATIONAHA.118.035516
7. Coutinho AD, Makenbaeva D, Farrelly E, Landsman-Blumberg PB, Lenihan D. Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States. Clinical Lymphoma, Myeloma & Leukemia. 2017;17(10):676–83. DOI: 10.1016/j.clml.2017.06.011
8. Buddeke J, Bots ML, van Dis I, Liem A, Visseren FLJ, Vaartjes I. Trends in comorbidity in patients hospitalised for cardiovascular disease. International Journal of Cardiology. 2017;248:382–8. DOI: 10.1016/j.ijcard.2017.06.106
9. Al-Kindi SG, Oliveira GH. Prevalence of Preexisting Cardiovascular Disease in Patients With Different Types of Cancer. Mayo Clinic Proceedings. 2016;91(1):81–3. DOI: 10.1016/j.mayocp.2015.09.009
10. Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular Disease Mortality Among Breast Cancer Survivors: Epidemiology. 2016;27(1):6–13. DOI: 10.1097/EDE.0000000000000394
11. Haque R, Prout M, Geiger AM, Kamineni A, Thwin SS, Avila C et al. Comorbidities and cardiovascular disease risk in older breast cancer survivors. The American Journal of Managed Care. 2014;20(1):86–92. PMID: 24512167
12. Hasin T, Gerber Y, McNallan SM, Weston SA, Kushwaha SS, Nelson TJ et al. Patients With Heart Failure Have an Increased Risk of Incident Cancer. Journal of the American College of Cardiology. 2013;62(10):881–6. DOI: 10.1016/j.jacc.2013.04.088
13. Boytsov S.A., Ipatov P.V., Kalinina A.M., Vergazova E.K., Tkacheva O.N., Gambaryan M.G. et al. Organization of medical examinations for certain groups of the adult population. Methodological recommendations for practical implementation of order of Ministry of health of Russian Federation of February 3, 2015 N 36an “on approval of the procedure for conducting medical examinations of certain groups of adult population”. - M. 2015, - 111c. Approved by the chief specialist in preventive medicine of the Russian Ministry of health on March 23, 2015. Av. at: http://docs.cntd.ru/document/420265578.
14. Zvolinskaia E.Yu., Kimitsidi M.G., Aleksandrov A.A. Analysis of the prevalence of cardiovascular risk factors in students. Russian Journal of Preventive Medicine and Public Health. 2015;18(6):53–7.
15. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation. 2016;133(11):1104–14. DOI: 10.1161/CIRCULATIONAHA.115.020406
16. Frayn K, Bernard S, Spalding K, Arner P. Adipocyte triglyceride turnover is independently associated with atherogenic dyslipidemia. Journal of the American Heart Association. 2012;1(6):e003467. DOI: 10.1161/JAHA.112.003467
17. Rodriguez-Iturbe B, Pons H, Quiroz Y, Johnson RJ. The Immunological Basis of Hypertension. American Journal of Hypertension. 2014;27(11):1327–37. DOI: 10.1093/ajh/hpu142
18. Golia E, Limongelli G, Natale F, Fimiani F, Maddaloni V, Pariggiano I et al. Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target. Current Atherosclerosis Reports. 2014;16(9):435. DOI: 10.1007/s11883-014-0435-z
19. Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K et al. High-Sensitivity C-Reactive Protein and Cardiovascular Disease. Journal of the American College of Cardiology. 2013;62(5):397–408. DOI: 10.1016/j.jacc.2013.05.016
20. Nishida Y, Kubota Y, Iso H, Tamakoshi A, the JACC Study Group. Self-Reported Eczema in Relation with Mortality from Cardiovascular Disease in Japanese: the Japan Collaborative Cohort Study. Journal of Atherosclerosis and Thrombosis. 2019;26(9):775–82. DOI: 10.5551/jat.46383
21. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12):1119–31. DOI: 10.1056/NEJMoa1707914
22. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. The Lancet. 2017;390(10105):1833–42. DOI: 10.1016/S0140-6736(17)32247-X
23. Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park, N.Y.). 2011;25(5):400–10, 413. PMID: 21710835
24. Choudhury AR, Singh KK. Mitochondrial determinants of cancer health disparities. Seminars in Cancer Biology. 2017;47:125–46. DOI: 10.1016/j.semcancer.2017.05.001
25. Birru Talabi M, Mackey RH, Kuller LH, Dorman JS, Deane KD, Robinson WH et al. Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women’s Health Initiative Rheumatoid Arthritis Study. American Journal of Epidemiology. 2017;186(2):245–54. DOI: 10.1093/aje/kwx087
26. Herrero Rivera D, Nieto-Guerrero Gómez JM, Cacicedo Fernández de Bobadilla J, Delgado D, Rivin del Campo E, Praena-Fernández JM et al. Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment. Clinical and Translational Oncology. 2019;21(9):1220–30. DOI: 10.1007/s12094-019-02047-5
27. Gendlin G.E., Ryazanceva E.E. Chronic heart failure and cancer risk: is there a relationship? Atmosphere. Cardiology news. 2013;4:21–4.
28. Thanan R, Oikawa S, Hiraku Y, Ohnishi S, Ma N, Pinlaor S et al. Oxidative Stress and Its Significant Roles in Neurodegenerative Diseases and Cancer. International Journal of Molecular Sciences. 2014;16(1):193–217. DOI: 10.3390/ijms16010193
29. Tan BL, Norhaizan ME, Liew W-P-P. Nutrients and Oxidative Stress: Friend or Foe? Oxidative Medicine and Cellular Longevity. 2018;2018:9719584. DOI: 10.1155/2018/9719584
30. Litwin SE. Cardiac Remodeling in Obesity. JACC: Cardiovascular Imaging. 2010;3(3):275–7. DOI: 10.1016/j.jcmg.2009.12.004
31. De Onis M, Lobstein T. Defining obesity risk status in the general childhood population: Which cut-offs should we use? International Journal of Pediatric Obesity. 2010;5(6):458–60. DOI: 10.3109/17477161003615583
32. Laskey R, McCarroll M, von Gruenigen V. Obesity-related endometrial cancer: an update on survivorship approaches to reducing cardiovascular death. BJOG: An International Journal of Obstetrics & Gynaecology. 2016;123(2):293–8. DOI: 10.1111/1471-0528.13684
33. Dobbins M, Decorby K, Choi BCK. The Association between Obesity and Cancer Risk: A Meta-Analysis of Observational Studies from 1985 to 2011. ISRN Preventive Medicine. 2013;2013:680536. DOI: 10.5402/2013/680536
34. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ et al. Body-Mass Index and Mortality among 1.46 Million White Adults. New England Journal of Medicine. 2010;363(23):2211–9. DOI: 10.1056/NEJMoa1000367
35. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjønneland A et al. Body Size and Risk of Colon and Rectal Cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). JNCI: Journal of the National Cancer Institute. 2006;98(13):920–31. DOI: 10.1093/jnci/djj246
36. Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K. Estrogen Receptors and Their Implications in Colorectal Carcinogenesis. Frontiers in Oncology. 2015;5:19. DOI: 10.3389/fonc.2015.00019
37. Ackerman SE, Blackburn OA, Marchildon F, Cohen P. Insights into the Link Between Obesity and Cancer. Current Obesity Reports. 2017;6(2):195–203. DOI: 10.1007/s13679-017-0263-x
38. Stefanou N, Papanikolaou V, Furukawa Y, Nakamura Y, Tsezou A. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. BMC Cancer. 2010;10(1):442. DOI: 10.1186/1471-2407-10-442
39. Hou N, Luo J-D. Leptin and cardiovascular diseases: Leptin and cardiovascular diseases. Clinical and Experimental Pharmacology and Physiology. 2011;38(12):905–13. DOI: 10.1111/j.1440-1681.2011.05619.x
40. Singh R, Devi S, Gollen R. Role of free radical in atherosclerosis, diabetes and dyslipidaemia: larger-than-life. Diabetes/Metabolism Research and Reviews. 2015;31(2):113–26. DOI: 10.1002/dmrr.2558
41. Alman AC, Talton JW, Wadwa RP, Urbina EM, Dolan LM, Hamman RF et al. Inflammation, adiposity, and progression of arterial stiffness in adolescents with type 1 diabetes: The SEARCH CVD Study. Journal of Diabetes and its Complications. 2018;32(11):995–9. DOI: 10.1016/j.jdiacomp.2018.08.004
42. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JPA. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607. DOI: 10.1136/bmj.g7607
43. Nagle CM, Crosbie EJ, Brand A, Obermair A, Oehler MK, Quinn M et al. The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer. Gynecologic Oncology. 2018;150(1):99–105. DOI: 10.1016/j.ygyno.2018.04.006
44. Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y et al. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. European Journal of Human Genetics. 2009;17(12):1668–75. DOI: 10.1038/ejhg.2009.86
45. Reed MJ, Beranek PA, Ghilchik MW, James VH. Estrogen production and metabolism in normal postmenopausal women and postmenopausal women with breast or endometrial cancer. European Journal of Cancer & Clinical Oncology. 1986;22(11):1395–400. DOI: 10.1016/0277-5379(86)90151-3
46. Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study: Menopause. 2018;25(1):11– 20. DOI: 10.1097/GME.0000000000000956
47. Jaroch J, Rzyczkowska B, Bociąga Z, Łoboz-Rudnicka M, Kruszyńska E, Rychard W et al. Arterial–atrial coupling in untreated hypertension. Blood Pressure. 2015;24(2):72–8. DOI: 10.3109/08037051.2014.986929
48. Stocks T, Van Hemelrijck M, Manjer J, Bjørge T, Ulmer H, Hallmans G et al. Blood Pressure and Risk of Cancer Incidence and Mortality in the Metabolic Syndrome and Cancer Project. Hypertension. 2012;59(4):802–10. DOI: 10.1161/HYPERTENSIONAHA.111.189258
49. Kang YS, Park YG, Kim BK, Han SY, Jee YH, Han KH et al. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. Journal of Molecular Endocrinology. 2006;36(2):377–88. DOI: 10.1677/jme.1.02033
50. Zhang P-Y, Xu X, Li X-C. Cardiovascular diseases: oxidative damage and antioxidant protection. European Review for Medical and Pharmacological Sciences. 2014;18(20):3091–6. PMID: 25392110
51. Radišauskas R, Kuzmickienė I, Milinavičienė E, Everatt R. Hypertension, serum lipids and cancer risk: A review of epidemiological evidence. Medicina. 2016;52(2):89–98. DOI: 10.1016/j.medici.2016.03.002
52. Lyu Z, Li N, Wang G, Feng X, Chen S, Su K et al. Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study. International Journal of Cancer. 2019;144(12):2972–84. DOI: 10.1002/ijc.32051
53. His M, Dartois L, Fagherazzi G, Boutten A, Dupré T, Mesrine S et al. Associations between serum lipids and breast cancer incidence and survival in the E3N prospective cohort study. Cancer Causes & Control. 2017;28(1):77–88. DOI: 10.1007/s10552-016-0832-4
54. Waluga M, Zorniak M, Fichna J, Kukla M, Hartleb M. Pharmacological and dietary factors in prevention of colorectal cancer. Journal of Physiology and Pharmacology. 2018;69(3). DOI: 10.26402/jpp.2018.3.02
55. Warner M, Gustafsson J-A. On Estrogen, Cholesterol Metabolism, and Breast Cancer. New England Journal of Medicine. 2014;370(6):572–3. DOI: 10.1056/NEJMcibr1315176
56. Andreassen OA, Zuber V, Thompson WK, Schork AJ, Bettella F, the PRACTICAL Consortium et al. Shared common variants in prostate cancer and blood lipids. International Journal of Epidemiology. 2014;43(4):1205–14. DOI: 10.1093/ije/dyu090
57. Morris PB, Ference BA, Jahangir E, Feldman DN, Ryan JJ, Bahrami H et al. Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes. Journal of the American College of Cardiology. 2015;66(12):1378–91. DOI: 10.1016/j.jacc.2015.07.037
58. Conklin DJ, Schick S, Blaha MJ, Carll A, DeFilippis A, Ganz P et al. Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation. American Journal of Physiology-Heart and Circulatory Physiology. 2019;316(4):H801–27. DOI: 10.1152/ajpheart.00591.2018
59. Cifkova R, Pitha J, Krajcoviechova A, Kralikova E. Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. International Journal of Cardiology. 2019;286:214–9. DOI: 10.1016/j.ijcard.2019.01.039
60. World Health Organisation. European Bureau. A global poll of adult population about tobacco consumption: Brief overview, 2016. Av. at: https://www.who.int/tobacco/surveillance/survey/gats/gats_2016-rus-executive-summary-Ru.pdf.
61. Jemal A, Vineis P, Bray F, Torre L, Forman D. The cancer atlas. 2nd edition. -Atlanta: American Cancer Society;2016. - 135 p. ISBN 978-1-60443-228-2
62. Kitami M, Ali MK. Tobacco, Metabolic and Inflammatory Pathways, and CVD Risk. Global Heart. 2012;7(2):121–8. DOI: 10.1016/j.gheart.2012.06.004
63. USDA. Scientific Report of the 2015 Dietary Guidelines Advisory Committee. Part D, Chapter 2. Dietary patterns, foods and nutrients, and health outcomes. Av. at: https://ods.od.nih.gov/pubs/2015_dgac_scientific_report.pdf.2015.
64. Magalhães B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: systematic review and meta-analysis. European Journal of Cancer Prevention. 2012;21(1):15–23. DOI: 10.1097/CEJ.0b013e3283472241
65. Garcia-Larsen V, Morton V, Norat T, Moreira A, Potts JF, Reeves T et al. Dietary patterns derived from principal component analysis (PCA) and risk of colorectal cancer: a systematic review and metaanalysis. European Journal of Clinical Nutrition. 2019;73(3):366–86. DOI: 10.1038/s41430-018-0234-7
66. Stampfer M, Jahn JL. Partnerships for Promoting Prevention. Circulation. 2013;127(12):1267–9. DOI: 10.1161/CIRCULATIONAHA.113.001288
67. Wang T, Lee HG. Advances in Research on cis-9, trans-11 Conjugated Linoleic Acid: A Major Functional Conjugated Linoleic Acid Isomer. Critical Reviews in Food Science and Nutrition. 2015;55(5):720–31. DOI: 10.1080/10408398.2012.674071
68. Schwingshackl L, Schwedhelm C, Galbete C, Hoffmann G. Adherence to Mediterranean Diet and Risk of Cancer: An Updated Systematic Review and Meta-Analysis. Nutrients. 2017;9(10):1063. DOI: 10.3390/nu9101063
69. Wood AD, Strachan AA, Thies F, Aucott LS, Reid DM, Hardcastle AC et al. Patterns of dietary intake and serum carotenoid and tocopherol status are associated with biomarkers of chronic low-grade systemic inflammation and cardiovascular risk. British Journal of Nutrition. 2014;112(8):1341–52. DOI: 10.1017/S0007114514001962
70. Lordan R, Tsoupras A, Zabetakis I. The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment. Advances in Nutrition. 2019;10(1):148–64. DOI: 10.1093/advances/nmy090
71. Baena Ruiz R, Salinas Hernández P. Diet and cancer: Risk factors and epidemiological evidence. Maturitas. 2014;77(3):202–8. DOI: 10.1016/j.maturitas.2013.11.010
72. Salehi B, Martorell M, Arbiser J, Sureda A, Martins N, Maurya P et al. Antioxidants: Positive or Negative Actors? Biomolecules. 2018;8(4):124. DOI: 10.3390/biom8040124
73. Toma A, Paré G, Leong DP. Alcohol and Cardiovascular Disease: How Much is Too Much? Current Atherosclerosis Reports. 2017;19(3):13. DOI: 10.1007/s11883-017-0647-0
74. O’Keefe JH, Bhatti SK, Bajwa A, DiNicolantonio JJ, Lavie CJ. Alcohol and Cardiovascular Health: The Dose Makes the Poison… or the Remedy. Mayo Clinic Proceedings. 2014;89(3):382–93. DOI: 10.1016/j.mayocp.2013.11.005
75. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V et al. Light alcohol drinking and cancer: a meta-analysis. Annals of Oncology. 2013;24(2):301–8. DOI: 10.1093/annonc/mds337
76. Zaridze D, Brennan P, Boreham J, Boroda A, Karpov R, Lazarev A et al. Alcohol and cause-specific mortality in Russia: a retrospective case–control study of 48 557 adult deaths. The Lancet. 2009;373(9682):2201–14. DOI: 10.1016/S0140-6736(09)61034-5
77. Matejcic M, Gunter MJ, Ferrari P. Alcohol metabolism and oesophageal cancer: a systematic review of the evidence. Carcinogenesis. 2017;38(9):859–72. DOI: 10.1093/carcin/bgx067
78. Che L, Li D. The Effects of Exercise on Cardiovascular Biomarkers: New Insights, Recent Data, and Applications. In: Exercise for Cardiovascular Disease Prevention and Treatment. Series Title: Advances in Experimental Medicine and Biology. [ISBN: 978-981-10-4306- 2. DOI: 10.1007/978-981-10-4307-9_3]. Xiao J, editor -Singapore: Springer Singapore;2017.
79. Nakitanda A.O., Xuereb G., Armstrong T. The increasing burden of non communicable diseases and the role of physical activity. Russian Journal of Preventive Medicine and Public Health. 2014;17(1):12–7.
80. Schmid D, Behrens G, Keimling M, Jochem C, Ricci C, Leitzmann M. A systematic review and meta-analysis of physical activity and endometrial cancer risk. European Journal of Epidemiology. 2015;30(5):397–412. DOI: 10.1007/s10654-015-0017-6
81. Zaridze D.G. Cancer prophylactics. Guidelines for doctors. -M.: IMAPress;2009. - 224 p. ISBN 978-5-904356-05-7
82. MacCallum-Carter L. Solving the Physical Inactivity Epidemic. Russian Journal of Preventive Medicine and Public Health. 2014;17(1):28–30.
83. Eriksson M, Johnson O, Boman K, Hallmans G, Hellsten G, Nilsson TK et al. Improved fibrinolytic activity during exercise may be an effect of the adipocyte-derived hormones leptin and adiponectin. Thrombosis Research. 2008;122(5):701–8. DOI: 10.1016/j.thromres.2008.01.010
84. Howard BJ, Hurtig-Wennlöf A, Olsson LA, Nilsson TK, Dunstan DW, Wennberg P. Self-Reported Sitting Time, Physical Activity and Fibrinolytic and Other Novel Cardio-Metabolic Biomarkers in Active Swedish Seniors. PLOS ONE. 2016;11(9):e0163409. DOI: 10.1371/journal.pone.0163409
85. Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, Rahimi HR, Tajfard M, Ferns G. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. Journal of Cellular Physiology. 2018;233(11):8508– 25. DOI: 10.1002/jcp.26791
Review
For citations:
Zvolinskaya E.Yu., Mamedov M.N., Potievskaya V.I., Ivanov S.A., Kaprin A.D. Role of modified cardiovascular risk factors in development of oncologic diseases. Kardiologiia. 2020;60(9):110-121. (In Russ.) https://doi.org/10.18087/cardio.2020.9.n910
Views:
1648
Email this article 
Post a Comment 
